International Journal of

Blood Research and DisordersISSN: 2469-5696

Early Online

 Open Access DOI:10.23937/2469-5696/1410074

Melphalan and Cytarabine as a Salvage Therapy in Children with Relapsed or Refractory Acute Leukemia

Malaval Carmen Isolde, MD, Queudeville Manon, MD, Döring Michaela, MD, Hartmann Ulrike, Dr. Pharm, Lang Peter, MD, Handgretinger Rupert, MD and Ebinger Martin, MD

Article Type: Research Article | First Published: March 16, 2022

In refractory or relapsed acute leukemia the achievement of a complete remission by a salvage therapy and the performance of allogeneic hematopoietic stem cell transplantation (HSCT) is in most cases the only treatment by which long term disease-free survival can be accomplished. With current salvage regimens a 5 year overall survival rate of 29% is obtained in children with relapsed acute myeloid leukemia (AML) and a 10 year overall survival rate of 36% in children with relapsed acute lymphobla...

 Open Access DOI:10.23937/2469-5696/1410073

Aplastic Anemia-Related Mortality in Brazil, 2000-2018

Augusto Hasiak Santo

Article Type: Case Report | First Published: January 14, 2022

Aplastic anemia (AA) is a rare and serious disease, potentially life-threatening, that affects hematopoietic stem and progenitor cells and is characterized by pancytopenia and a hypoplastic bone marrow. The development of AA result from the destruction of hematopoietic cells by three main mechanisms, including direct environmental injury, dysregulated immune system, and primary inherited or acquired bone marrow failure syndrome. There are no AA specific markers then the diagnosis is reached by e...

Volume 9
Issue 1